TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05781217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triptorelin, goserelin, leuprorelin
Description: ADT will consist of LHRH analogues (triptorelin, goserelin, leuprorelin) with bicalutamide 50 mg/day started 10 days before the first ADT injection to avoid LHRH-related flare-ups. Bicalutamide will be discontinued after 30 days. The LHRH analogue will be initiated prior to the start of radiotherapy and administered for 6 or 24 months depending on treatment allocation. The maximum time permitted between randomisation and administration of the first LHRH dose is 30 days. The maximum time from the first LHRH dose to the start of SRT is 60 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triptorelin, goserelin, leuprorelin
Description: ADT will consist of LHRH analogues (triptorelin, goserelin, leuprorelin) with bicalutamide 50 mg/day started 10 days before the first ADT injection to avoid LHRH-related flare-ups. Bicalutamide will be discontinued after 30 days. The LHRH analogue will be initiated prior to the start of radiotherapy and administered for 6 or 24 months depending on treatment allocation. The maximum time permitted between randomisation and administration of the first LHRH dose is 30 days. The maximum time from the first LHRH dose to the start of SRT is 60 days.
Study: NCT03552796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant EphB4-HSA Fusion Protein
Description: Given intravesically
Study: NCT05671913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control arm
Study: NCT04637698

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OH2 injection
Description: Oncolytic Type 2 Herpes Simplex Virus
Study: NCT06005389

Intervention type: PROCEDURE
Intervention: cryotherapy
Description: Every patient had a cryotherapy session every 2 weeks until complete clearance for a maximum of six sessions and follow-up was done at 3 months after treatment completion to detect any recurrence. Each wart was frozen using the spray technique by CRY-AC Liquid Nitrogen Dispenser Brymill, USA for 10 to 30 seconds until a 1- to 2-mm ice ball halo was formed surrounding the targeted area.

Intervention type: DIAGNOSTIC_TEST
Intervention: serum Galectin-3 assay
Description: From each patient and control, 3 ml venous blood was withdrawn under complete aseptic conditions before treatment and 2 weeks after the last treatment session by a disposable plastic syringe; the collected blood was placed on a plain tube without anticoagulant for 30 min at room temperature till coagulation occurs; after this, centrifugation of tubes was done for 20 min at 1000 rpm. The serum was separated into an aliquot and placed at -20 degrees Celsius for further analysis. Serum Gal-3 was measured using human Galectin-3 enzyme-linked immunosorbent assay (ELISA) kits supplied by ELK Biotechnology CO., LTD, Wuhan, China, catalog number (ELK2790) based on the Sandwich-ELISA technique as per the manufacturer's instructions.

Intervention type: DIAGNOSTIC_TEST
Intervention: serum Galectin-3 assay
Description: From each patient and control, 3 ml venous blood was withdrawn under complete aseptic conditions before treatment and 2 weeks after the last treatment session by a disposable plastic syringe; the collected blood was placed on a plain tube without anticoagulant for 30 min at room temperature till coagulation occurs; after this, centrifugation of tubes was done for 20 min at 1000 rpm. The serum was separated into an aliquot and placed at -20 degrees Celsius for further analysis. Serum Gal-3 was measured using human Galectin-3 enzyme-linked immunosorbent assay (ELISA) kits supplied by ELK Biotechnology CO., LTD, Wuhan, China, catalog number (ELK2790) based on the Sandwich-ELISA technique as per the manufacturer's instructions.
Study: NCT04586504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Description: 5 mg/mL concentration of midazolam. Maximum dose = 10 mg. Administered using a mucosal atomization device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Description: 5 mg/mL concentration of midazolam. Maximum dose = 10 mg. Administered using a mucosal atomization device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Description: 5 mg/mL concentration of midazolam. Maximum dose = 10 mg. Administered using a mucosal atomization device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Description: 5 mg/mL concentration of midazolam. Maximum dose = 10 mg. Administered using a mucosal atomization device.
Study: NCT04825769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LLLT（Low Level Laser Therapy）
Description: 2 times a day, 3 minutes each time, with an interval of more than 4 hours. During the semester: From Monday to Friday, set up an intervention room in the school; For winter and summer vacation: everyday at home
Study: NCT05265910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olopatadine hydrochloride ophthalmic solution 0.7%
Description: Pataday® Once Daily Relief Extra Strength (eyedrop)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: loratadine 10 mg
Description: Claritin® Tablets 24-Hour (tablet)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tears Naturale
Description: Tears Naturale® II (eyedrop)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablet (tablet)
Study: NCT06470412

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-Guided Group
Description: Participants receive supplement prescriptions determined by GenAIS, an AI system which considers genetic data, metabolic profiles, biochemical markers, and patient history.
Study: NCT06503094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19&CD20 bispecific CAR-T cells
Description: Each patient will receive CD19\&CD20 bispecificCAR-T cells by intravenous infusion on day 0.
Study: NCT04880447

Intervention type: BIOLOGICAL
Intervention: BNT162b2
Description: COMIRNATY is administered intramuscularly after dilution as a course of 2 doses (0.3 mL each). It is recommended to administer the second dose 3 weeks after the first dose.
Study: NCT05029466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive a single dose of psilocybin and be assessed weekly for six weeks and biweekly for 18 weeks. Participants who relapse may receive up to two repeated doses of psilocybin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive a single dose of psilocybin and be assessed weekly for six weeks and biweekly for 18 weeks. Participants who relapse may receive up to two repeated doses of psilocybin.
Study: NCT05953779

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinician-administered Need-focused Single Session Intervention
Description: All single-session interventions will be 90-minutes in length. At the conclusion of the intervention session, participants will receive suggestions for daily homework practice to complete and a flash drive with a copy of their session audio to review at their discretion. They will also meet with the therapist for a 10-minute remote check-in two weeks following the single session. All interventions include standard psychoeducational components. Both the standard intervention and the specific ones were designed to be broadly efficacious for depression and anxiety symptomatology. The psychosocial needs which serve as the focus of the interventions are derived from motivation and affect regulation models.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician-administered Need-focused Single Session Intervention
Description: All single-session interventions will be 90-minutes in length. At the conclusion of the intervention session, participants will receive suggestions for daily homework practice to complete and a flash drive with a copy of their session audio to review at their discretion. They will also meet with the therapist for a 10-minute remote check-in two weeks following the single session. All interventions include standard psychoeducational components. Both the standard intervention and the specific ones were designed to be broadly efficacious for depression and anxiety symptomatology. The psychosocial needs which serve as the focus of the interventions are derived from motivation and affect regulation models.
Study: NCT05949996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A nurse-led symptom distress screening program
Description: Five implementation strategies will be conducted individually for each of the study unit at the timepoint when the study unit is being randomly allocated to the implementation condition. For each study unit, all nurses will first receive a half-day training. Each study unit under the implementation condition will receive weekly audit and feedback reports to summarize the proportion of eligible patients, proportion of eligible patients being screened, proportion of patients appropriately referred to JCICC. The senior research assistant with a nursing background will receive training and mentoring from the PI and will be the guided facilitator. The guided facilitator will conduct weekly site visits to address operational issues arise during the implementation. Lastly, while the choice of symptom assessment tool and referral criteria are standardized and cannot be modified, the routine workflow for each study unit can be adjusted according to its context and resources.
Study: NCT05835089

Intervention type: DIAGNOSTIC_TEST
Intervention: serum kisspeptin levels
Description: Evaluation of the serum level of LH, FSH, prolactin, Testosterone (in boys), estradiol (in girls) and Kisspeptin levels

Intervention type: DIAGNOSTIC_TEST
Intervention: serum kisspeptin levels
Description: Evaluation of the serum level of LH, FSH, prolactin, Testosterone (in boys), estradiol (in girls) and Kisspeptin levels
Study: NCT06007638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3876602
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3876602
Description: Administered IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV.
Study: NCT06006325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture treatment
Description: Patients received acupuncture on both sides of the Zusanli (ST36) acupuncture points, and after Deqi , the needle was connected to an electro-acupuncture device (Hwato, Suzhou Medical ). The EA stimulation lasted for 30 min.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture treatment
Description: The participants in the SHAM-EA group performed shallow punctures at the bilateral non-acupuncture points, did not perform the Deqi operation, and were connected to the electroacupuncture stimulator but not energized.
Study: NCT05009160

Intervention type: DEVICE
Intervention: dreaMS App R2.1
Description: The Healios+Me platform App which contains the dreaMS App will be downloaded by all participants and all participants (PwMS and HC) will follow the same schedule

Intervention type: DEVICE
Intervention: dreaMS App R2.1
Description: The Healios+Me platform App which contains the dreaMS App will be downloaded by all participants and all participants (PwMS and HC) will follow the same schedule
Study: NCT03049787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Protocol
Description: Home exercise therapy protocol given to patient to be completed at home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy Protocol
Description: Formal physical therapy protocol to be given to physical therapist working with patient to direct formal intervention along with a home therapy protocol.
Study: NCT04583891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IntelliCare
Description: IntelliCare is a self-guided, fully automated suite of 6 apps designed for brief, frequent check-ins to promote skill acquisition. IntelliCare has been shown in both general deployment and human-supported trials to be efficacious in reducing symptoms of depression and anxiety.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: The Patient Education app will contain content relevant for general distress management. This includes information about thoughts/worries, prevalence of mood symptoms, CBT strategies for coping with negative affect, and other information typical of education-based mental health apps. The structure of this app will closely mirror patient education websites and apps which mimic the form and structure of apps that target cancer survivors and that primarily provide educational information about cancer and related symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: The randomization of added coaching vs. no added coaching after 1 week will only be carried out in the IntelliCare group. Coaching is a human supported approach to optimizing the use and benefit of the IntelliCare apps.
Study: NCT05085665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: single dose, 150 ug/kg
Study: NCT06176170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VividWhite Glaucoma Implant (VW-51)
Description: Subconjunctival surgical implantation of the VW-51 implant in the study eye.
Study: NCT00528255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol Vaginal Insert (MVI 100)
Description: The MVI 100 is misoprostol 100 mcg, formulated in a sustained release, nonbiodegradeable hydrogel polymer, with a polyester knit retrieval tape; IV oxytocin is permitted ad lib 30 minutes following removal of the MVI assuming no contraindications.
Study: NCT06041386

Intervention type: DRUG
Group type: OTHER
Intervention: Mepolizumab
Description: Mepolizumab will be prescribed based on physician decision.

Intervention type: OTHER
Group type: OTHER
Intervention: Spirometry
Description: Lung function via spirometry will be collected.
Study: NCT06360809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation exercise program
Description: After the allocation, the intervention will consist of a prehabilitation program lasting 4 weeks. Each week, there will be three sessions, with one being face-to-face and the other two being unsupervised sessions but with online video-support. Face-to-face sessions will be organized in small groups, and each patient of the PEP group will have an individualized plan based on data obtained during the initial assessment. Each session will include a combination of strength training and moderate aerobic training in a circuit format with movements especially involving the upper body.
Study: NCT04423913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of embolization beads
Description: Patients will receive embolization beads, loaded with doxorubicin or not.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of embolization beads
Description: Patients will receive embolization beads, loaded with doxorubicin or not.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of embolization beads
Description: Patients will receive embolization beads, loaded with doxorubicin or not.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of embolization beads
Description: Patients will receive embolization beads, loaded with doxorubicin or not.
Study: NCT05781568

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker dosage
Description: The simultaneous dosage of the 3 serum biomarkers will be performed at the Clinical Pathology Laboratory, using the instrument: µTASWakoTM i30 (Micro Total Analysis System) - Fujifilm.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker dosage
Description: The simultaneous dosage of the 3 serum biomarkers will be performed at the Clinical Pathology Laboratory, using the instrument: µTASWakoTM i30 (Micro Total Analysis System) - Fujifilm.
Study: NCT05339321

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SCG101
Description: SCG101 is an autologous HBV-specific T cell receptor engineered T cell therapy.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SCG101
Description: SCG101 is an autologous HBV-specific T cell receptor engineered T cell therapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD1/PD-L1 checkpoint inhibitor
Description: Commercially approved for HCC treatment.
Study: NCT05453019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Implant
Description: The surgeon will make a small cut (incision) behind patient's ear, and form a small hole in the portion of skull bone (mastoid) where the internal device rests. Then the surgeon create a small opening in the cochlea in order to thread the electrode of the internal cochlear implant device. The skin incision is stitched closed so that the internal device is under the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cochlear Implant
Description: The surgeon will make a small cut (incision) behind patient's ear, and form a small hole in the portion of skull bone (mastoid) where the internal device rests. Then the surgeon create a small opening in the cochlea in order to thread the electrode of the internal cochlear implant device. The skin incision is stitched closed so that the internal device is under the skin.
Study: NCT04817891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS
Description: Participants will receive HD-tDCS at up to 4 mA per channel for 20 minutes for 10 sessions. Dose determined through individualized computational models.
Study: NCT04257383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugira Muryango
Description: Strong Families, Thriving Children Sugira Muryango is a home-visiting intervention that empowers low-income families enrolled in Rwanda's social protection system to support early childhood development and healthy family functioning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugira Muryango
Description: Strong Families, Thriving Children Sugira Muryango is a home-visiting intervention that empowers low-income families enrolled in Rwanda's social protection system to support early childhood development and healthy family functioning.
Study: NCT04268043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flexible laryngeal airway mask
Description: Ventilation with flexible laryngeal mask airway

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: proseal laryngeal mask airway
Description: Ventilation with proseal laryngeal mask airway
Study: NCT05803616

Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid biopsy
Description: ctDNA measured in the plasma and analyse by next generation sequencing (NGS) for minimal residual disease (MRD)
Study: NCT05302583

Intervention type: OTHER
Group type: OTHER
Intervention: Aromatherapy Inhaler
Description: Lavender Aromatherapy Inhaler Peppermint Aromatherapy Inhaler

Intervention type: OTHER
Group type: OTHER
Intervention: Aromatherapy Inhaler
Description: Lavender Aromatherapy Inhaler Peppermint Aromatherapy Inhaler
Study: NCT04939662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib+Bevacizumab to SCLC patients
Description: Olaparib 300 mg bid per os every 12 hours D1-21 administered in each cycle days. One cycle consists of 21 days.~Bevacizumab 15 mg/kg via IV administered on Day1 of each cycle. One cycle is consisted of 21 days.~The subject's body weight criterion is based on C1D1 (first dose date), and if more than 10% of BW is increased and decreased, the drug dose is changed to that BW.
Study: NCT05026710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone (Coloplast Imajin Hydro) ureteral stent
Description: During the end of the standard of care ureteroscopy the silicone stent will be placed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer)
Description: During the end of the standard of care ureteroscopy the Non-silicone (Polyurethane/Percuflex) stent will be placed.
Study: NCT05374720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: salpingectomy
Description: Removal of one of the fallopian tubes.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: hysterectomy
Description: remove the uterus, whole or only part. It may also involve the removal of the cervix, ovaries, fallopian tubes and other surrounding structures.
Study: NCT06232928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early Class II elastics
Description: Participants were treated by a fixed orthodontic appliance with intermaxillary class II elastics to correct the class II malocclusion. patients were instructed to wear immediate light short Class II elastics from upper canines to lower second premolars for 24 hours except while eating and change the elastics every 12 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Class II elastics
Description: patients were treated by a fixed orthodontic appliance with intermaxillary Class II elastics. patients were instructed to wear Class II elastics from upper canines to lower first molars for 24 hours except while eating and change the elastics every 12 hours after reaching to rigid stainless steel arch wires.
Study: NCT06198842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Treosulfan 21mg/m2 (days -6, -5, -4)
Study: NCT06252233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient- and physician-centered QoL monitoring
Description: Electronic QoL monitoring including QoL diagnosis and therapy (pain therapy, psychotherapy, social support, nutrition, physiotherapy, fitness, respiratory counselling, palliative care). Patients and treating physicians have access to the results of their QoL monitoring and to a network of local healthcare providers.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Electronic QoL monitoring without QoL diagnosis and therapy. Patients and treating physicians have no access to the results of their QoL monitoring. The therapist network is also available for control arm.